HUP9901005A2 - Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B - Google Patents

Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B

Info

Publication number
HUP9901005A2
HUP9901005A2 HU9901005A HUP9901005A HUP9901005A2 HU P9901005 A2 HUP9901005 A2 HU P9901005A2 HU 9901005 A HU9901005 A HU 9901005A HU P9901005 A HUP9901005 A HU P9901005A HU P9901005 A2 HUP9901005 A2 HU P9901005A2
Authority
HU
Hungary
Prior art keywords
polypeptides
glycoprotein
herpes virus
antibodies
well
Prior art date
Application number
HU9901005A
Other languages
English (en)
Inventor
Marnix L. Bosch
Timothy M. Rose
Kurt Strand
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of HUP9901005A2 publication Critical patent/HUP9901005A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát a gamma-herpeszvírűsők RFHV/KSHV alcsaládjábatartőzó vírűsőkból származó glikőprőtein-b-pőlipeptideket kódőlóizőlált pőlinűkleőtidők képezik, valamint az azőkat tartalmazórekőmbináns klónőzóvektőrők és expressziós vektőrők, a találmányszerinti pőlinűkleőtidőkkal vagy vektőrőkkal transzfőrmáltgazdasejtek, a találmány szerinti glikőprőtein-b-pőlipeptidekkelszembeni mőnőklőnális és izőlált pőliklőnális ellenanyagők, atalálmány szerinti pőlipeptideket, pőlinűkleőtidőkat vagyellenanyagőkat tartalmazó vakcinák, valamint a találmány szerintiglikőprőtein-B-t kódőló szekvenciával megegyező szekvenciájú vagyazzal hibridizálódó őligőnűk-leőtidők. A találmány tárgyát képeziktővábbá herpeszvírűs-fertőzés kezelésére, glikőprőtein-B kódőlópőlinűkleőtid amplifikálására alkalmas eljárásők, valamint mintákbanvírűs-DNS vagy -RNS kiműtatására alkalmas eljárásők diagnősztikűsreagenskészletek, herpeszvírűs-pőlinűkleőtidők, antiherpeszvírűsellenanyagők vagy herpesz- vírűs-pőlipeptidek kiműtatására biőlógiaimintákban, tővábbá eljárásők herpeszvírűs-fertőzöttség kiműtatására. Atalálmány tárgyát képezik tővábbá eljárásők annak meghatárőzására,hőgy valamely pőtenciális gyógyászati hatóanyag alkalmas-e gamma-herpeszvírűs-fertőzés kezelésére, valamint glikőprőtein-B-pőlipeptidekés ilyen pőlipeptideket kódőló pőlinűkleőtidők előállítására. Atalálmány szerinti pőlinűkleőtidők, pőlipeptidek és ellenanyagőkalkalmasak gamma-herpeszvírűs-fertőzés kiműtatására és kezelésérevalamint glikőprőtein-B-pőlipeptiddel szembeni imműnválaszelőidézésére. ŕ
HU9901005A 1995-09-26 1996-09-26 Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B HUP9901005A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US429795P 1995-09-26 1995-09-26

Publications (1)

Publication Number Publication Date
HUP9901005A2 true HUP9901005A2 (hu) 1999-07-28

Family

ID=21710088

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901005A HUP9901005A2 (hu) 1995-09-26 1996-09-26 Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B

Country Status (11)

Country Link
US (2) US6022542A (hu)
EP (1) EP0852624A2 (hu)
JP (1) JPH11514864A (hu)
KR (1) KR19990063761A (hu)
CN (1) CN1214080A (hu)
AU (1) AU7382796A (hu)
BR (1) BR9610785A (hu)
CA (1) CA2233060A1 (hu)
HU (1) HUP9901005A2 (hu)
MX (1) MX9802356A (hu)
WO (1) WO1997012042A2 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932066B2 (en) 1994-08-18 2011-04-26 The Trustees Of Columbia University In The City Of New York Unique associated kaposi's sarcoma virus sequences and uses thereof
JP2002513274A (ja) * 1996-07-25 2002-05-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク カポジ肉腫関連ウイルスのユニークな配列およびその使用
US6348586B1 (en) 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US6461811B1 (en) * 1999-07-08 2002-10-08 Biotransplant, Inc. Gamma-herpes virus DNA and methods of use
IT1320168B1 (it) * 2000-03-13 2003-11-18 Univ Ferrara Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US7388093B2 (en) * 2001-01-06 2008-06-17 The General Hospital Corporation Gene for identifying individuals with familial dysautonomia
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20130071837A1 (en) * 2004-10-06 2013-03-21 Stephen N. Winters-Hilt Method and System for Characterizing or Identifying Molecules and Molecular Mixtures
EP1853294A4 (en) * 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd ANTIANGIOGENIC COMPOUNDS
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8188256B2 (en) * 2006-05-02 2012-05-29 Wako Pure Chemical Industries, Ltd. Primer and probe for detection of Mycobacterium intracellulare
CA2694824A1 (en) 2007-08-09 2009-02-12 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
US11857622B2 (en) * 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
DE3461928D1 (en) * 1983-06-23 1987-02-12 Person Stanley Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
US4642333A (en) * 1983-09-16 1987-02-10 Stanley Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein B of herpes virus types 1 and 2
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
AU641121B2 (en) * 1988-01-29 1993-09-16 Chiron Corporation Recombinant CMV neutralizing proteins
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US5558988A (en) * 1992-11-13 1996-09-24 Thomas Jefferson University Primers and methods for detecting mutations in the procollagen II gene that indicate a genetic predisposition for osteoarthritis

Also Published As

Publication number Publication date
EP0852624A2 (en) 1998-07-15
AU7382796A (en) 1997-04-17
MX9802356A (es) 1998-07-31
US6051375A (en) 2000-04-18
KR19990063761A (ko) 1999-07-26
CN1214080A (zh) 1999-04-14
BR9610785A (pt) 1999-07-13
WO1997012042A2 (en) 1997-04-03
US6022542A (en) 2000-02-08
CA2233060A1 (en) 1997-04-03
JPH11514864A (ja) 1999-12-21
WO1997012042A3 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
Bhatia et al. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas
Bonneau et al. Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity
Carter et al. Defective translation of measles virus matrix protein in a subacute sclerosing panencephalitis cell line
US4803072A (en) Immunomodulation
BR9712592A (pt) Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico
CO4750842A1 (es) Pox virus recombinantes de mapache y vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina .
JP2009529576A5 (hu)
Sawyer et al. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
Aspden et al. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector
EP0554389A4 (en) Molecular clones of hiv-1 and uses thereof
HUP0500722A2 (hu) Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
US5800981A (en) Human cytomegalovirus antigen and its use
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
Hondo et al. Genome variation among varicella-zoster virus isolates derived from different individuals and from the same individuals
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
Charan et al. Transforming growth factor‐β induced by live or ultraviolet‐inactivated equid herpes virus type‐1 mediates immunosuppression in the horse
Monteil et al. Effective priming of neonates born to immune dams against the immunogenic pseudorabies virus glycoprotein gD by replication-incompetent adenovirus-mediated gene transfer at birth
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
Fogdell-Hahn et al. Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients
Kos et al. Induction of primary anti‐viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin‐7
AR020092A1 (es) Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido
KR900701291A (ko) 혈호균속 인플루엔자용 백신과 진단검사법
ATE189702T1 (de) Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
Kwang et al. Analysis of antibody response to ovine lentivtrus by using viral gene products expressed in a prokaryotic system